Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.

Antimicrobial agents and chemotherapy - 1 Aug 2011

Farrell David J, Mendes Rodrigo E, Ross James E, Sader Helio S, Jones Ronald N

Abstract excerpt

The LEADER Program monitors the in vitro activity of linezolid in sampled U.S. medical centers using reference broth microdilution methods with supporting molecular investigations in a central laboratory design. This report summarizes data obtained in 2009, the 6th consecutive year of this longitudinal study. A total of 6,414 isolates from 56 medical centers in all nine Census regions across the United States...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Enterococcus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interspersed Repetitive Sequences

Share to Linezolid

Share to Oxazolidinones

Share to Staphylococcus

Share to Streptococcus

Share to Streptococcus agalactiae

Source

Open in PubMed Open full text

Identifiers

PMID: 21670176
DOI: 10.1128/AAC.01729-10
PMCID: PMC3147616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.PMID 21670176Read ↗

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).Semantic proximity Read ↗

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)Semantic proximity Read ↗

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countriesSemantic proximity Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.Semantic proximity Read ↗

The emerging problem of linezolid-resistant <i>Staphylococcus</i>Semantic proximity Read ↗

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesSemantic proximity Read ↗

Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureusSemantic proximity Read ↗

Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12)Semantic proximity Read ↗

Mechanisms of Linezolid Resistance among Coagulase-Negative Staphylococci Determined by Whole-Genome SequencingSemantic proximity Read ↗

Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, ChinaSemantic proximity Read ↗

Molecular Characteristics and Antimicrobial Resistance of Linezolid-Resistant Staphylococcus aureus in Osteoarticular Infections: A 11-Year Study From a Hospital in Xi’anSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.